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Abstract
Background: The use of artemisinin derivatives has increased exponentially with the deployment
of artemisinin combination therapy (ACT) in all malarious areas. They are highly effective and are
considered safe, but in animal studies artemisinin derivatives produce neurotoxicity targeting
mainly the auditory and vestibular pathways. The debate remains as to whether artemisinin
derivatives induce similar toxicity in humans.
Methods: This prospective study assessed the effects on auditory function of a standard 3-day oral
dose of artesunate (4 mg/kg/day) combined with mefloquine (25 mg/kg) in patients with acute
uncomplicated falciparum malaria treated at the Shoklo Malaria Research Unit, on the Thai-
Burmese border. A complete auditory evaluation with tympanometry, audiometry and auditory
brainstem responses (ABR) was performed before the first dose and seven days after initiation of
the antimalarial treatment.
Results: Complete auditory tests at day 0 (D0) and day 7 (D7) were obtained for 93 patients.
Hearing loss (threshold > 25 dB) on admission was common (57%) and associated with age only.
No patient had a threshold change exceeding 10 dB between D0 and D7 at any tested frequency.
No patient showed a shift in Wave III peak latency of more than 0.30 msec between baseline and
D7.
Conclusion: Neither audiometric or the ABR tests showed clinical evidence of auditory toxicity
seven days after receiving oral artesunate and mefloquine.
Background
Artemisinin derivatives, mostly artesunate and arte-
mether, have been widely used in China and South-East
Asia for the past 15 years, and are now recommended in
combination therapy, in all malarious areas to prevent
further spread of resistance [1]. In Thailand, the National
Malaria Programme has used artesunate in combination
with mefloquine as first line treatment for uncomplicated
Published: 6 November 2008
Malaria Journal 2008, 7:233 doi:10.1186/1475-2875-7-233
Received: 20 March 2008
Accepted: 6 November 2008
This article is available from: http://www.malariajournal.com/content/7/1/233
© 2008 Carrara et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Malaria Journal 2008, 7:233 http://www.malariajournal.com/content/7/1/233
Page 2 of 9
(page number not for citation purposes)
falciparum malaria since 1995 along the Thai-Burmese
border [2,3]. This regimen has proved to be highly effec-
tive against multiple-drug resistant parasite strains, and its
cure rate has remained above 90% since its introduction
[4,5].
Clinical studies including thousands of patients con-
firmed that artemisinin-based combination therapies
were safe and well tolerated in patients [6,7]. However, in
animal studies, artemisinin derivatives have been consist-
ently associated with neuronal damage, particularly in
areas of the brainstem involved in hearing and gait con-
trol [8-13]. Neuropathological lesions were seen after pro-
longed administration of oral, intra-muscular and
parental artemisinin compounds, but were more frequent
after intra-muscular injection of oil-based arteether and
artemether, than after parental or oral administration of
artesunate [14-16]; clinical manifestations following oral
administration of artemisinin derivatives were seen only
at high doses [12]. In 1997, retrospective studies in Thai-
land [17] and in Vietnam [18] have specifically investi-
gated the potential adverse effect on brainstem function in
patients having been exposed to artemisinins. Patients
were, in both studies, compared to controls who had not
been treated with an artemisinin and who were living in
the same environment and they were matched by age and
sex; audiology results were similar in both groups and no
neurological anomalies were found. However, concerns
about safety of the artemisinin-based combinations have
been raised following a retrospective study in Mozam-
bique published in 2004 [19]. The authors reported a
mild hearing loss across all but the two lowest audible fre-
quencies in a non-randomised retrospective study of 150
construction site workers who had received artemether-
lumefantrine. Audiograms were routinely performed on
induction and cessation of employment. Audiology
results of patients having received artemether-lumefan-
trine were compared to those from employees unexposed
to this drug combination and matched by age, gender,
weight and race. A negative change between the two audi-
ograms was systematically seen among those having
received artemether-lumefantrine, varying from -6.50 dBL
to – 0.07 dBL. To further explore this issue the auditory
function of 68 subjects treated with artemether-lumefan-
trine within the previous five years, and 68 age and sex-
matched controls were assessed by the Shoklo Malaria
Research Unit (SMRU), between October 2004 and March
2005. This retrospective study failed to show any differ-
ence in auditory function between the two groups [20].
More recently, two prospective studies evaluated the
potential audiotoxicity of a standard oral dose of arte-
mether-lumefantrine; one in 15 healthy volunteers fol-
lowed up 8 days after treatment [21] and one in Ethiopian
patients followed up for a period of 90 days [22]; neither
study found pathological changes in audiometric pure-
tone thresholds or ABR peak latencies following arte-
mether-lumefantrine.
The present study aimed to evaluate prospectively the
potential effects of artesunate in combination with meflo-
quine on the auditory function of patients with acute
uncomplicated falciparum malaria treated in one of the
SMRU clinic for migrant workers along the Thai-Burmese
border.
Methods
Study site and study population
The study took place in the SMRU clinic located in Wang
Pha, a village bordering Burma. The village is in an agri-
cultural area of low malaria endemicity. The SMRU clinic
offers clinical care to a large migrant population mostly
coming from adjacent Burmese villages. Patients who had
a positive rapid diagnosis test (Paracheck-Pf®, Orchid Bio-
medical Systems, Goa, India) were eligible for the study
provided that they gave fully informed consent. A malaria
smear was then performed to confirm the diagnosis of
uncomplicated falciparum malaria. Severely ill patients,
and hyperparasitaemic patients (4% or more parasites per
1,000 red blood cells on a thin malaria smear) were
excluded from further tests, as well as those without Plas-
modium falciparum parasites detected on the malaria smear
or with a parasite count lower than five parasites per 500
white blood cells.
A medical history was taken and all previous antimalarial
treatments verified against medical records. Patients with
a history of severe or cerebral malaria, head trauma, coma
or unconsciousness episode, chronic ear pathology or
chronic neurological disorder, and those having taken
drugs such as mefloquine, loop diuretics, or aminoglyco-
side antibiotics in the previous two months were
excluded. All subjects were then assessed for a concomi-
tant illness, and those with acute upper respiratory infec-
tion were also excluded. Patients with fever received
paracetamol prior to the auditory tests performed by
trained examiners. This investigation was part of a series
of studies on the potential toxicity of antimalarial drugs,
approved by the Ethical Committees of Oxford University
(OXTREC) and Mahidol University (Bangkok).
Audiology tests
A locally made sound proof chamber was available in the
field setting, and special care was taken to reduce ambient
noise as much as possible. Temperature and ventilation
was maintained at 25°C by air conditioning during work-
ing hours; it was routinely turned off during the audiom-
etry and the ABR tests. Ambient noise measured at the
level of the test subject's head was within the American
National Standard for maximum ambient noise levels for
audiometric test rooms (ANSI 3.1–199).Malaria Journal 2008, 7:233 http://www.malariajournal.com/content/7/1/233
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Otoscopy and tympanometry
Otoscopic examination was performed before testing.
Patients with eardrum perforation, acute ear infection or
severe scarring of the tympanic membrane were excluded.
Tympanometry was done using a Madsen™, Zodiac 901
tympanometer. Patients with an abnormal tympanometry
at the day of enrolment such as a "type B" (flat wave),
"type C" (wave peak shifted to the left with a middle ear
pressure (MEP) lower than – 150 daP), or a wave peak
with oscillations, in one or both ears were excluded and
further tests were not performed. The mobility of the tym-
panic membrane was evaluated by the amplitude of the
compliance peak.
Audiometry
The audiometer used was a Madsen™, Orbiter 922 desk-
top. Pure-tone air conduction thresholds were obtained
for each ear separately using insert earphone to limit fur-
ther the effect of ambient noise. The unmasked thresholds
were established at 0.25, 0.5, 1, 2, 3, 4, 6 and 8 kHz using
the modified Hughson-Westlake ascending procedure
[23]. Subjects with abnormal hearing (pure-tone air con-
duction thresholds > 25 decibels (dB) at any tested fre-
quency in either or both ears) were included in the study
if the difference between the right and the left ear Wave V
latency peaks was smaller than 0.20 msec. Patients with
asymmetric hearing (a difference between ears of > 15 dB
in pure-tone air conduction thresholds at three or more
continuous frequencies), and those recalling a recent
exposure to sustained loud noises and presenting with a
pure-tone air conduction threshold of > 25 dB at frequen-
cies of 2000 Hz and above were excluded from the study.
Auditory brainstem response (ABR)
The ABR test was performed using a portable computer-
ized system (Bio-logic Navigator Pro AEP). Gold surface
electrodes were applied to the vertex, both mastoids and
the forehead. Patients rested on a wooden bed, and were
allowed to relax before testing. Electrode impedance was
checked before each test run and was maintained at <
5,000 Ohms for all electrodes. Impedance difference
between electrodes was maintained at < 2,000 Ohms. A
rarefaction click-stimulus was used to elicit the auditory
evoked potentials. The duration of one click was 100 μs
and the clicks were presented monoaurally at a rate of
11.1 per second with an intensity of 80 dB. A total of 2048
sweeps were recorded by the computer and results aver-
aged. A contra lateral masking with 40 dB white noise was
used. At least two replications were made to determine
reliability. The procedure was performed for each ear sep-
arately. The waveforms were labeled I, III, V for the ipsilat-
eral recording (tested-ear). The peak latency (PL) for each
wave was established and the inter-peak latencies (IPL) (I
to III, III to V and I to V) calculated automatically. Patients
with inconclusive ABR tests (no reproducible or measura-
ble waveforms), those with more than 10% artifacts dur-
ing each run or for whom electrode impedance could not
be maintained below requested values were excluded
from the study.
Treatment
All patients were treated with three days of artesunate (4
mg/kg/day), and mefloquine (25 mg/kg) given on the sec-
ond (15 mg/kg) and third day (10 mg/kg) of treatment.
Female patients of child bearing age had a pregnancy test
prior to receiving antimalarial treatment. The first dose of
treatment was received after all the auditory tests were per-
formed and was supervised. If a patient vomited, a full
dose was given again if the vomit was within half an hour
of receiving the medication, and half a dose if it occurred
between half an hour and an hour after. Patients unable
to tolerate the drugs after three attempts had their medica-
tion changed and were excluded from the study. The two
next doses were unsupervised, unless the patient had
agreed to come daily to the clinic for the treatment, a prac-
tice commonly accepted in this setting where compliance
is > 90%. No drug levels were done during the study.
Follow up procedure
All patients who had completed the baseline (Day 0)
auditory tests and tolerated their medication well were
asked to come for a follow-up a week later (Day 7). A sim-
ple physical assessment was done, malaria smear was
taken in patients with symptoms such as fever or head-
ache, and the complete set of auditory tests was performed
again.
Statistical analysis
The primary endpoint of the study was based on ABR
using Wave III, as it was expected to be the most sensitive
parameter to detect any artemisinin derivative-induced
toxicity [24,25]. A change from Day 0 in ABR Wave III
peak latency in either or both ears of > 0.30 msec was con-
sidered as significant [26,27]. The range of pure-tone air
conduction thresholds testing variability is usually within
5 dB; therefore, a threshold difference exceeding 10 dB
between Day 0 and Day 7 was adopted as clinically signif-
icant.
If a patient had treatment failure, experienced a change in
tympanometry, developed an ear infection, or had a sig-
nificant change in the pure-tone air conduction thresh-
olds at Day 7, the ABR results were not accepted.
Continuous normally distributed data were described by
their mean and their standard deviation (SD), non-nor-
mally distributed data by their median, and range. Per-
centages were given for categorical data, which were
compared using the Chi-square test with Yates' continuity
correction or the Fisher's exact test. Paired t-test or Wil-Malaria Journal 2008, 7:233 http://www.malariajournal.com/content/7/1/233
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coxon signed rank test were used to compare continuous
variables. Demographic characteristics, treatment dose
and clinical findings were analyzed in univariate analysis,
or with Pearson's correlation, to evaluate possible factors
associated with hearing loss at baseline, and changes in
audiometry and ABR at Day 7.
All data were double entered using Microsoft Access, Ver-
sion 2000 and analyzed using SPSS for Windows (SPSS
Inc, Chicago, Illinois, USA), Version 11.0.
Results
One hundred and sixty-one patients were enrolled in the
study between June 2005 and December 2006, 49 were
excluded and 12 lost for follow up (Figure 1). One hun-
dred (62%) were followed at Day 7 and 93 (58%) com-
pleted the auditory tests and were entered in the final
analysis. Their general characteristics are presented in
Table 1. One patient was not clinically cured at Day 7
(1%); the malaria smear at Day 7 confirmed the presence
of P. falciparum parasites.
Tympanometry
Tympanometry was performed for all patients. Six
patients with MEP values >-150 daP or with oscillations at
baseline were excluded from the study. Two patients had
an abnormal tympanometry at Day 7 (MEP >-150 daP);
tympanometric values of the remaining patients were
unchanged at Day 7 compared to baseline.
Audiometry
Twelve patients were excluded after completion of the
auditory tests: eleven on admission and one at Day 7 fol-
low-up. Five of them had a threshold difference between
left and right ear of more than 15 dB at three or more fre-
quencies; four had at least one pure-tone air conduction
threshold above 25 dB and a wave V inter-latency > 0.20
msec on ABR, and the three last patients with abnormal
results reported a recent loud noise exposure.
Air-conduction threshold median values and their range
by frequencies for the remaining patients are presented in
Figure 2. Hearing loss (threshold > 25 dB) in at least one
tested frequency in one or both ears was present among
57.0% (53/93) patients, ranging from 1 to 8 frequencies
(median: 2 frequencies); hearing loss was bilateral in 33/
53 patients (62%); when unilateral, right or left ears were
equally affected. The hearing impairment involved high
frequencies (6 and 8 kHz) in the majority of cases (44/53,
83%). Threshold values were between 30 and 40 dB for 45
of those patients (85%), equivalent to a mild hearing loss
according to the American National Standards Institute
(ANSI S3.6, 1996), between 45 and 70 dB for 7 (13%) or
moderate hearing loss, and at 85 dB for 1 patient (severe
hearing loss). Hearing loss was associated in univariate
analysis to age (P < 0.001), but not to sex, body weight,
temperature, parasitaemia, tympanometry results, or time
to last artesunate treatment.
Nine of the 53 patients with one or more pure-tone air
conduction thresholds above 25 dB at baseline returned
to thresholds within normal limits at Day 7, and 12 had
Table 1: Baseline characteristics of the study population having completed Day 7 follow-up (n = 93)
Patients' characteristics All patients
Male (n = 74) 79.6%
Age (in years)a 26.6 (8.8) [13–53], 13.7 – 41.2
Weight (in kg)a 50.7 (7.1) [30.0–70.0], 39.7 – 63.0
Tympanic temperature (in °C)a 37.2 (1.1) [34.9–40.1], 35.8 – 39.0
Mixed infection, PF+PV (n = 16) 17.2%
Geometric mean parasite count per μl [range] 7386 [79–190546]
Total artesunate dose (in mg)b 600 [300–825]
Previous artesunate treatment (n = 26) 28%
Time of last artesunate treatment (in month)b 4 [1 – 8]
Tympanometry characteristics
Middle ear pressure, left ear (in daP)b -15 [-145 – +25]
Middle ear pressure, right ear (in daP)b -15 [-140 – +95]
Static compliance, left ear (in ml)b 0.48 [0.16–3.08]
Static compliance, right ear (in ml)b 0.46 [0.15–2.52]
Tympanometric gradient, left ear (dimensionless)a 0.49 (0.15) [0.19–0.83], 0.22 – 0.77
Tympanometric gradient, right ear (dimensionless)a 0.46 (0.15) [0.09–0.81], 0.23 – 0.74
a Mean value, with (SD), [range], 5th and 95th percentiles without brackets
b Median, [range]Malaria Journal 2008, 7:233 http://www.malariajournal.com/content/7/1/233
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Patients flow diagram Figure 1
Patients flow diagram.
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at least one tested frequency returning to a threshold ≤ 25
dB. Three patients had a unilateral change from 25 dB to
30 dB (2 patients) and from 25 to 35 dB (1 patient) at the
highest frequency (8,000 Hz) between baseline and Day
7. Nobody had a threshold change exceeding 10 dB
between Day 0 and Day 7 at any tested frequency. Overall,
there was an improvement of 0.9 dB to 1.8 dB in all air-
conduction thresholds at Day 7 on the left ear (statistically
significant at all but 3,000 Hz frequency), and 0.4 to 1.5
dB on the right ear, statistically significant at all but 3 fre-
quencies (3,000, 6,000 and 8,000 Hz). This improvement
was correlated with the intensity of fever at baseline (r =
0.23, P < 0.001), but not with the level of parasitaemia (r
= 0.026, P = 0.12). The total expected dose of artesunate
or mefloquine received did not affect the hearing thresh-
old changes, and neither did the severity of hearing loss at
baseline.
Auditory brainstem response
After completion of the ABR, nineteen patients were
excluded at baseline and two at Day 7 of follow-up (Figure
1). Ninety-three paired ABR were analyzed. Mean peak
latencies and interpeak latencies for both ears separately
are presented in Table 2. There was a small but significant
difference in Wave I peak latency between ears at baseline
(mean value left ear 1.52 msec vs. 1.55 msec on the right,
P = 0.006); this difference became non-significant at Day
7. No patient showed a shift in Wave III peak latency of
more than 0.30 msec between baseline and Day 7. How-
ever, there was a small (within 1 SD of the baseline), but
Pure-air tone conduction thresholds at Day 0 and Day 7, both ears separately Figure 2
Pure-air tone conduction thresholds at Day 0 and Day 7, both ears separately. Air-conduction threshold is given as 
median values with [range], dBL.
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clear delay in peak Wave I–III and V latencies at Day 7
compared to baseline. Delay in peak Wave I–III and V
latencies was present in 74% (69/93), 80% (74/93) and in
81% (75/93) of patients respectively. Peak Wave III and V
latencies delay was more likely to be bilateral (62% vs.
38%, P = 0.005 and 64% vs. 36%, P = 0.001). Among
those, 17 patients (29%) had a bilateral delay in all three
peak Wave latencies and 19 others (33%) had a bilateral
delay in peak Wave III and V. Patients with fever ≥ 37.5°C
on admission were more likely to have a delay in Wave III
and V peak latencies than those without fever (42% vs.
11%, P = 0.02 and 41% vs. 11%, P = 0.03 respectively) and
this delay was more pronounced, 0.1 msec vs. 0.04 msec
for Wave III and 0.1 msec vs. 0.05 msec for Wave V peak
latencies, P = 0.002 and P = 0.003 respectively. Delayed
peak latencies were not artesunate or mefloquine dose-
dependant, and were not associated with sex or age of the
patients, their parasitaemia on admission, tympanometry
results, hearing loss or changes in the air conduction
thresholds between admission and Day 7.
Discussion
The artemisinin derivatives are essential in the treatment
of uncomplicated falciparum malaria, and they are more
effective than quinine in severe malaria [28]; their use
worldwide has increased at an exponential rate as drug
resistance spreads. Artemisinin compounds are consid-
ered safe and well tolerated [6,7]. The main concern about
toxicity comes from experimental studies on animals.
Those studies have consistently found a neurotoxic effect
on certain brainstem nuclei and cerebellar roof nuclei
involved in hearing and gait control [10,12]. This toxicity
appears to be dose-dependant and varies according to the
mode of administration; oil-based compounds such as
artemether and arteether, administered intra-muscular,
are more toxic than intravenous water-soluble artesunate
or oral administration of any of the above substances
[9,11,15,29,30].
This study is the first prospective study assessing the
effects on auditory function of a standard oral dose of
artesunate (4 mg/kg/day) combined with mefloquine (25
mg/kg) in patients with uncomplicated falciparum
malaria. There was a small improvement at all tested fre-
quencies in both ears seven days after initiation of treat-
ment, correlated to the degree of fever on admission. This
improvement was not substantial enough to be spontane-
ously reported by any of the patients and could also have
been the result of a learning effect and a better concentra-
tion during the test after fever resolution. A similar
improvement was found in the study of Gurkov et al. in
patients treated with artemether-lumefantrine and fol-
lowed up 90 days [22].
Three patients had a measurable reduction in hearing
threshold (5 dB for 2 patients and 10 dB for the last one);
however none complained of a hearing loss. Although
those findings remain unexplained they seem unlikely to
be due to an ototoxic drug effect (asymmetric hearing loss,
at the highest frequency only). Overall our audiometry
results are similar to the results reported by Mc Call et al.
among 15 healthy volunteers who underwent experimen-
tal malaria and received artemether-lumefantrine [21].
ABR peak latencies and inter-peak latencies measures (the
primary endpoint of this study) were similar at baseline to
those reported by previous studies conducted along the
Thai-Burmese border [17,20]. A minimal, but significant,
prolongation of all Wave peak latencies was observed at
Day 7, but not of the inter-peak latency III–V, which
would have been prolonged in case of artemisinin toxic-
ity, according to the results from the animal studies. There
was no relationship between total dose of artesunate
received, or of mefloquine, and Wave peaks delay. On the
other hand, patients with fever on admission were more
likely to have a prolongation of Wave peak latencies at
Day 7 compared to baseline. Changes in body tempera-
Table 2: Auditory Brainstem Responses (ABR) at Day 0 and Day 7, for both ears separately
Peak latencies Inter-latencies
Wave I Wave III Wave V I–III III–V I–V
Day 0
Left ear 1.52 (0.14) 3.67 (0.15) 5.45 (0.22) 2.15 (0.16) 1.78 (0.17) 3.93 (0.24)
Right ear 1.55 (0.13) 3.65 (0.14) 5.44 (0.23) 2.10 (0.16) 1.79 (0.17) 3.89 (0.25)
Day 7
Left ear 1.55 (0.14) 3.73 (0.16) 5.51 (0.22) 2.18 (0.17) 1.78 (0.17) 3.96 (0.24)
Right ear 1.57 (0.13) 3.71 (0.14) 5.54 (0.23) 2.14 (0.17) 1.82 (0.17) 3.97 (0.25)
Difference D7-D0
Left ear 0.03 (0.07) 0.07 (0.09) 0.07 (0.11) 0.04 (0.10) 0.00 (0.08) 0.04 (0.12)
P value < 0.001 < 0.001 < 0.001 0.001 0.892 0.003
Right ear 0.02 (0.06) 0.07 (0.08) 0.09 (0.13) 0.05 (0.08) 0.03 (0.11) 0.07 (0.13)
P value 0.003 < 0.001 < 0.001 < 0.001 0.017 < 0.001
Presented as mean, (SD), units are in msec.Malaria Journal 2008, 7:233 http://www.malariajournal.com/content/7/1/233
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ture affect the evoked potentials and an increase in tem-
perature tends to reduce the peak latencies for all waves,
in animals [31-33], during exercise [34], and in sick
patients [35], a phenomenon which could explain the
findings of this study.
The ABR test is a sensitive method to detect abnormalities
along the auditory pathway, and was well tolerated even
by sick patients. It failed to show a significant change in
inter-peak latency III–V or any abnormally delayed Wave
III peak latency after completion of the antimalarial treat-
ment.
At baseline, a majority of the patients enrolled in the study
presented with some hearing loss in the high frequencies
(6–8 kHz) associated with age only. This finding remains
unexplained, but does not appear to be related to prior
exposure to artesunate. It could be due to a combination
of factors such as aging, noise-exposure, prior use of anti-
biotics and smoking, all frequently found in this popula-
tion, and all of which might be involved in high
frequencies auditory deficit [36-40].
Conclusion
The results of this prospective study are reassuring and do
not support the hypothesis of a toxic effect of the artesu-
nate or the mefloquine on the auditory pathway.
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